These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 2778836)
1. Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. Gabizon A; Shiota R; Papahadjopoulos D J Natl Cancer Inst; 1989 Oct; 81(19):1484-8. PubMed ID: 2778836 [TBL] [Abstract][Full Text] [Related]
2. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Gabizon AA Cancer Res; 1992 Feb; 52(4):891-6. PubMed ID: 1737351 [TBL] [Abstract][Full Text] [Related]
3. Enhanced tumor targeting of doxorubicin by ganglioside GM1-bearing long-circulating liposomes. Unezaki S; Maruyama K; Ishida O; Takahashi N; Iwatsuru M J Drug Target; 1993; 1(4):287-92. PubMed ID: 8069570 [TBL] [Abstract][Full Text] [Related]
4. Influence of lipid composition on the antitumor activity exerted by doxorubicin-containing liposomes in a rat solid tumor model. Storm G; Roerdink FH; Steerenberg PA; de Jong WH; Crommelin DJ Cancer Res; 1987 Jul; 47(13):3366-72. PubMed ID: 3581073 [TBL] [Abstract][Full Text] [Related]
5. Sonosensitive dioleoylphosphatidylethanolamine-containing liposomes with prolonged blood circulation time of doxorubicin. Evjen TJ; Hagtvet E; Nilssen EA; Brandl M; Fossheim SL Eur J Pharm Sci; 2011 Jul; 43(4):318-24. PubMed ID: 21620968 [TBL] [Abstract][Full Text] [Related]
6. Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes. Harasym TO; Cullis PR; Bally MB Cancer Chemother Pharmacol; 1997; 40(4):309-17. PubMed ID: 9225948 [TBL] [Abstract][Full Text] [Related]
7. The influence of physical characteristics of liposomes containing doxorubicin on their pharmacological behavior. Goren D; Gabizon A; Barenholz Y Biochim Biophys Acta; 1990 Nov; 1029(2):285-94. PubMed ID: 2245212 [TBL] [Abstract][Full Text] [Related]
8. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Charrois GJ; Allen TM Biochim Biophys Acta; 2004 May; 1663(1-2):167-77. PubMed ID: 15157619 [TBL] [Abstract][Full Text] [Related]
9. Comparative plasma and tissue distribution of Sun Pharma's generic doxorubicin HCl liposome injection versus Caelyx Burade V; Bhowmick S; Maiti K; Zalawadia R; Jain D; Rajamannar T Cancer Chemother Pharmacol; 2017 May; 79(5):899-913. PubMed ID: 28349166 [TBL] [Abstract][Full Text] [Related]
10. Enhanced delivery of doxorubicin to tumor by long-circulating thermosensitive liposomes and local hyperthermia. Maruyama K; Unezaki S; Takahashi N; Iwatsuru M Biochim Biophys Acta; 1993 Jul; 1149(2):209-16. PubMed ID: 8323940 [TBL] [Abstract][Full Text] [Related]
11. Enhanced delivery and antitumor activity of doxorubicin using long-circulating thermosensitive liposomes containing amphipathic polyethylene glycol in combination with local hyperthermia. Unezaki S; Maruyama K; Takahashi N; Koyama M; Yuda T; Suginaka A; Iwatsuru M Pharm Res; 1994 Aug; 11(8):1180-5. PubMed ID: 7971721 [TBL] [Abstract][Full Text] [Related]
12. [Cationic liposomes loaded with doxorubicin targeting to the tumor neovasculature in vitro]. Zhao W; Ma HL; Qi XR Yao Xue Xue Bao; 2007 Sep; 42(9):982-8. PubMed ID: 18050743 [TBL] [Abstract][Full Text] [Related]
13. Kinetic analysis of tissue distribution of doxorubicin incorporated in liposomes in rats (II). Harashima H; Midori Y; Ohshima S; Yachi K; Kikuchi H; Kiwada H Biopharm Drug Dispos; 1993 Oct; 14(7):595-608. PubMed ID: 8251614 [TBL] [Abstract][Full Text] [Related]
14. A comparative study on the antitumor effect, cardiotoxicity and nephrotoxicity of doxorubicin given as a bolus, continuous infusion or entrapped in liposomes in the Lou/M Wsl rat. Storm G; van Hoesel QG; de Groot G; Kop W; Steerenberg PA; Hillen FC Cancer Chemother Pharmacol; 1989; 24(6):341-8. PubMed ID: 2791187 [TBL] [Abstract][Full Text] [Related]
15. Intravenous pretreatment with empty pH gradient liposomes alters the pharmacokinetics and toxicity of doxorubicin through in vivo active drug encapsulation. Mayer LD; Reamer J; Bally MB J Pharm Sci; 1999 Jan; 88(1):96-102. PubMed ID: 9874708 [TBL] [Abstract][Full Text] [Related]
16. Development of pH-sensitive liposomes that efficiently retain encapsulated doxorubicin (DXR) in blood. Ishida T; Okada Y; Kobayashi T; Kiwada H Int J Pharm; 2006 Feb; 309(1-2):94-100. PubMed ID: 16364578 [TBL] [Abstract][Full Text] [Related]
17. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection. Ishida T; Atobe K; Wang X; Kiwada H J Control Release; 2006 Oct; 115(3):251-8. PubMed ID: 17045355 [TBL] [Abstract][Full Text] [Related]
18. Optimization and upscaling of doxorubicin-containing liposomes for clinical use. Amselem S; Gabizon A; Barenholz Y J Pharm Sci; 1990 Dec; 79(12):1045-52. PubMed ID: 2079648 [TBL] [Abstract][Full Text] [Related]
19. In vivo antitumor activity of cis-bis-neodecanoato-trans-R,R-1, 2-diaminocyclohexane platinum(II) formulated in long-circulating liposomes. Mori A; Wu SP; Han I; Khokhar AR; Perez-Soler R; Huang L Cancer Chemother Pharmacol; 1996; 37(5):435-44. PubMed ID: 8599866 [TBL] [Abstract][Full Text] [Related]
20. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv. Cheng WW; Allen TM J Control Release; 2008 Feb; 126(1):50-8. PubMed ID: 18068849 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]